Basima Sh. Alghazali¹
Preeclampsia (PE), a human-pregnancy-specific disease defined as the occurrence of hypertension and significant protein urea in a previously healthy woman on or after the 20th week of gestation, although its main etiology is still unknown many biochemical markers have been studded one of them is serum inhibin A. Aim of the study is to evaluate the association of maternal serum levels of inhibin A in pregnancy complicated by preeclampsia and compare it with normal non preeclamptic pregnancy and to study its usefulness in the detection of its severity. Prospective case control study of maternal human inhibin A level in pregnant women with preeclampsia in comparison with the control group in Al- Zahra Maternity Teaching Hospital. The women included in this study were divided into two groups, 50 control group who are normotensive and 50 preeclamptic patient which further divided into mild and sever. In each group cardiovascular, renal connective tissue diseases were excluded. A complete clinical history was taken from each women including; maternal age, parity, gestational age, and blood sample was taken for biochemical and hematological investigation. The blood samples were sent for liver function test, renal function test, complete blood picture and Inhibin A level. The level of inhibin A in both forms of preeclampsia, severs and mild is 154.9474±16.45767 and 150.0774±8.21035 respectively, which is significantly higher than normal control group (103.9600±14.76080). Together these data confirmed that the level of inihibin A was greater in preeclampsia than in normal pregnancy which may prove to be clinically useful laboratory markers for detection of preeclampsia.
Keywords: Preeclampsia; Pregnancy; Inhibin A
Copyright © 2016 by The American Society for BioMedicine and BM-Publisher, Inc.
- Masoura S, Kalogiannidis IA, Gitas G, et al. Biomarkers in pre-eclampsia: A novel approach to early detection of the disease. J Obstet Gynaecol 2012;32:609-616. [PubMed]
- Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365(9461):785-99. [PubMed]
- Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Molecular Aspects of Medicine 2007;28(2):227-244. [Abstract/Full-Text]
- Muttukrishna S, North RA, Morris J, et al. Serum inhibin A and activin A are elevated prior to the onset of preeclampsia. Hum Reprod 2000;15:1640-1645. [PubMed]
- Gratacos E, Casals E, Gomez O, et al. Inhibin A serum levels in proteinuric and nonproteinuric pregnancy-induced hypertension: Evidence for placental involvement in gestational hypertension? Hypertens Pregnancy 2000;19:315-321. [Abstract/Full-Text]
- Harshini Vana, Suchitra Thunga, Comparison of inhibin a levels in preeclampsia and normal pregnancy: Preeclampsia and inhibin A levels, A prospective study. Int J Pharm 2012.
- William, B poulter NR, Brown MJ, et al. Guideline for management of the fourth working party of the British hypertension society, 2004 BHJ. JHUM Hypertensions 2004;18;139-85.7;161-76. [Abstract/Full-Text]
- Eknoyan G. Adolphe Quetelethe the average man and indices of obesity. Nephrology Dialysis Transplantation 2007;23:47-51. [PubMed]
- Machado S, Neves M, Freitas L, Compos M. Diagnosis, pathophysiology and management of preeclampsia: a review. Port J Nephrol Hypert 2013;27:153-161. [Abstract/Full-Text]
- Mazaki-Tovi S, Romero R, Kim SK, et al. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J Matern Fetal Neonatal Med 2010;23(8):857-68. [PubMed]
- Waugh J, Smith MC, Edmonds DK. Hypertension disorder. Dewhurst’s textbook of obstetrics & gynaecology for postgraduates, 8th edition, Willey-Blackwell publishing 2012;chapter 11:101-109.
- Mylonas B. Schiessl U, Jeschke J, et al. Expression of inhibin/activin subunits alpha (-α), BetaA (-βA), and BetaB (-βB) in placental tissue of normal, preeclamptic, and HELLP pregnancies. Endocrine Pathology 2006;17:19-33. [Abstract/Full-Text]
- Shen Z, Cai L, Suprapto I, Shenoy P, Zhou X. Placental and maternal serum inhibin A in patients with preeclampsia and small-for-gestational-age. Journal of Obstetrics and Gynaecology Research 2011;37(10):1290-1296. [PubMed]
- Shin-Young Kim, Hyun-MeeRyu, Jae-Hyug Yang, et al. Maternal Serum and Amniotic Fluid Inhibin A Levels in Women who Subsequently Develop Severe Preeclampsia. J Korean Med Sci 2006;21(3):452-456. [PubMed]
- Paiwattananupant KM, Phupong V. Serum Inhibin A Level in Preeclampsia and Normotensive Pregnancy. Hypertension in Pregnancy 2008;27(4):337-343. [Abstract/Full-Text]
- Zwahlen M. Gerber S. Bersinger NA. First Trimester Markers for Pre-Eclampsia: Placental vs. Non-Placental Protein Serum Levels. GynecolObstet Invest 2007;63:15-21. [PubMed]
- Silver HM, Lambert-Messerlian GM, Reis FM, et al. Mechanism of increased maternal serum total activin a and inhibin a in preeclampsia. J Soc Gynecol Investig 2002;9(5):308-12. [PubMed]
- Lambert-Messerlian GM, Silver HM, Petraglia F. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancy. J Soc Gynecol Investig 2000;7(3):170-4. [PubMed]
- Bersinger NA, Smárason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 2003;22(1):45-55. [PubMed]
- Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA. Serum Activin A, Inhibin A, and Follistatin concentrations in preeclampsia or small for gestational age pregnancies. Obstet Gynecol 2002;99(2):267-74. [PubMed]
READ THE FULL ARTICLE
Access this article in full PDF format [Full-Text/PDF]
Thank you for visiting American Journal of BioMedicine. * = Required fields
American Journal of BioMedicine Volume 4, Issue 10, pages 435-442
Received June 29, 2016; accepted September 30, 2016; published October 26, 2016
How to cite this article
Alghazali BS. Inhibin A level in the detection of preeclampsia and its severity. American Journal of BioMedicine 2016;4(10):435-442.
Email this link to a friend
Add article to my folders
Alert me when this article is cited
Add to portfolio
Contact with editor